Chemo-Free Therapy for Follicular Lymphoma

Rituximab plus lenalidomide provided similar responses to rituximab plus chemotherapy in previously untreated patients.

Immunochemotherapy has been the standard of care for high-tumor-burden, symptomatic patients with follicular lymphoma (FL) for many years.

Now, investigators have conducted an industry-sponsored, international, randomized, superiority phase III trial (RELEVANCE) to compare the efficacy and safety of induction therapy with the noncytotoxic combination of rituximab plus lenalidomide (R-Len) versus standard rituximab (R) plus chemotherapy (R-chemo; investigator's choice of R-CVP, R-CHOP, or R-bendamustine) in 1030 treatment-naive FL patients. Following completion of induction, maintenance therapy was administered for 2 years in each treatment arm. The primary endpoints were complete remission (CR) at 120 weeks and progression-free survival (PFS…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Chemo-Free Therapy for Follicular Lymphoma

Topics

Reviewing Author